Covid-19 vaccine delivers adrenaline boost for stockmarkets
The news that 50 million doses of Pfizer's Covid-19 vaccine could be ready by the end of the year and 1.3 billion by 2021 has sparked euphoria on world markets.

Pfizer’s vaccine trial has delivered a “shot of adrenaline for the markets”, says Russ Mould of AJ Bell. Fifty million doses could be ready by the end of the year and 1.3 billion by 2021, raising hopes that an end to the pandemic is finally in sight. The news caused euphoria on world markets, with the MSCI All-Country World Index closing at an all-time high and America’s S&P 500 setting a new record on Monday.
The FTSE 100 broke through the 6,000 level, rising more than 6% over the first two trading days of the week to register its highest closing level since June. The pan-European Stoxx 600 hit an eight-month high. Oil prices leapt by 9% and Japan’s Nikkei hit a 29-year peak (see page 7).
The wheel of fortune turns
Yet not all stocks were shining. America’s tech-heavy Nasdaq Composite Index fell by 1.5% on Monday, with Zoom, which has benefited from the work-from-home boom, plunging by almost 20%. By contrast, stocks hit hard by Covid-19 enjoyed a return to favour. In London, food-travel specialist SSP Group gained 52%, with aircraft engine maker Rolls-Royce up 43%.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The sudden shift away from tech stocks was the “biggest single-day market rotation I’ve witnessed” in 30 years covering markets, says John Authers on Bloomberg. The FAANG (Facebook, Amazon, Apple, Netflix and Google’s parent company, Alphabet) stocks have soared this year, but on Monday they underperformed the average S&P 500 stock by almost 8%. This sudden reversal could be the start of the long-predicted reflation trade, which would see investors shift away from expensive tech and into cheaper, more cyclical stocks.
Rising Covid-19 case numbers on both sides of the Atlantic could yet bring another bout of stockmarket turbulence, says Louis-Vincent Gave of Gavekal Research. But the market is “eager to turn the page” on the pandemic. Talk of a return to normal early next year means we could be heading for “an unprecedented economic rebound”. For long-suffering value investors things are finally looking up (see page 20).
The future is bright
The Pfizer news may prove “the beginning of the end” of the pandemic, but we still have a long way to go, says Cormac Mullen on Bloomberg. The “consensus view” is the same now as before the Pfizer update: a vaccine will come, but it will be “deep into 2021” before it is widely available.
Investors are right to be cheerful, says Robin Winkler of Deutsche Bank. The vaccine’s reported 90% efficacy is “at least as good as the best-case scenario” and government pre-orders mean that Pfizer is well-positioned to meet global demand. Finally, with vaccines from the likes of AstraZeneca and Moderna still in trials we don’t have all our eggs in one basket.
For now, investors are content to bask in the “warm glow” of good news, says Simon Jack for BBC News. Stockmarkets are about the future, and the vaccine results mean tomorrow looks better than today. “While the virus is not yet beaten it is beatable.”
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
The Palace of Westminster is falling down
The Palace of Westminster is in need of repair, but the bill is prohibitive, says Simon Wilson
-
'It’s time to buy British equities'
Opinion There is no better place to start investing in UK equities than with two of MoneyWeek’s favourite investment trusts, says Max King
-
Sotheby’s fishes for art collectors – will it succeed?
Sotheby’s is seeking to restore confidence in the market after landing Leonard Lauder's art collection, including Gustav Klimt's Portrait of Elisabeth Lederer
-
How to cash in on overlooked British bargains offering both income and growth
Opinion Sue Noffke, manager of the Schroder Income Growth Fund, selects three UK stocks where she’d put her money